<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205137</url>
  </required_header>
  <id_info>
    <org_study_id>0502-0612</org_study_id>
    <nct_id>NCT03205137</nct_id>
  </id_info>
  <brief_title>Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice</brief_title>
  <official_title>Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy Based on Database Data in Real-world Japanese Therapeutic Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the medication adherence measured by PDC of
      patients with FDC or double-pill combination therapy in real-world Japanese therapeutic
      practice.The further objective of this study is how much influence the background of patients
      to the adherence.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of days covered of patients treated with single- and double- combination therapy</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demographic and clinical characteristics of patients treated with single- and double combination</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">3275</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan and hydrochlorothiazide group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan and amlodipine group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan+hydrochlorothiazide double-pill combination group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>telmisartan+amlodipine double-pill combination group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subjects treated with telmisartan/hydrochlorothiazide</intervention_name>
    <description>subjects treated with telmisartan/hydrochlorothiazide</description>
    <arm_group_label>Telmisartan and hydrochlorothiazide group</arm_group_label>
    <other_name>MICARDIS, PRITOR, TELMISARTAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subjects treated with Telmisartan and amlodipine</intervention_name>
    <description>Subjects treated with Telmisartan and amlodipine</description>
    <arm_group_label>Telmisartan and amlodipine group</arm_group_label>
    <other_name>MICARDIS, PRITOR, TELMISARTAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group</intervention_name>
    <description>subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group</description>
    <arm_group_label>Telmisartan+hydrochlorothiazide double-pill combination group</arm_group_label>
    <other_name>MICARDIS, PRITOR, TELMISARTAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subjects treated with telmisartan+amlodipine double pill</intervention_name>
    <description>subjects treated with telmisartan+amlodipine double pill</description>
    <arm_group_label>telmisartan+amlodipine double-pill combination group</arm_group_label>
    <other_name>MICARDIS, PRITOR, TELMISARTAN</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Japan Medical Information Research Institute (JMIRI), Inc. prescription database is used.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hypertension

          -  Patients must have their first prescription (defined as index date*) for telmisartan
             and hydrochlorothiazide or Micombi® between 01/07/2010 and 28/09/2010

          -  Patients must have their first prescription (defined as index date*) for telmisartan
             and amlodipine or Micamlo® between 10/12/2010 and 09/03/2011

          -  Patients must have at least 180 days follow up verified by the presence of
             prescription record

        Exclusion Criteria:

          -  Patients who were under 40 years old at the time of enrolment

          -  Patients who prescribed the study drugs less than 90 days during a follow up period of
             180 days

          -  Patients whose visits are less than 2 times during a follow up period of 180 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nippon Boehringer Ingelheim Co., Ltd.</name>
      <address>
        <city>Tokyo</city>
        <zip>141-6017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <contact>
      <last_name>Seiichiro Nishimura</last_name>
      <phone>81364172157</phone>
      <email>seiichiro.nishimura@boehringer-ingelheim.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Telmisartan amlodipine combination</mesh_term>
    <mesh_term>Telmisartan, hydrochlorothiazide drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

